Clozapine clinical toolkit optimizes inpatient clozapine monitoring

• Egile Nagusiak: Brooke Gessner, PharmD, ACPR (Egilea), Michelle Carter, RN, MSN (Egilea), Kiana Rahnama, BSc, PharmD, ACPR (Egilea), Alberto Almeida, MPH, PMP (Egilea), Colleen Borralho, MHS, BSPN, BA, RPN (Egilea), Tamara Mihic, BSc, ACPR, PharmD (Egilea), Joan C. Y. Ng, BSc, ACPR, PharmD (Egilea), Joseph H. Puyat, MA, MSc, PhD (Egilea), Angela Russolillo, PhD, MSc, RPN (Egilea), Katelyn C. Halpape, BSP, ACPR, PharmD, BCPP (Egilea)
• Formatua: Liburua
• Argitaratua: American Association of Psychiatric Pharmacists, 2024-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Introduction Clozapine is the most effective antipsychotic in the management of treatment-resistant schizophrenia; however, its use is challenging due to the risk of severe adverse effects. Despite the risks associated with clozapine, there is no mandatory monitoring in Canada beyond hematologic tes...